Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Witty’s Bonus Slashed As GSK Recovers From China Scandal

This article was originally published in PharmAsia News

Executive Summary

Still learning lessons from 2013's bribery scandal and subsequent investigations in China, GlaxoSmithKline's CEO Sir Andrew Witty had his annual bonus for the past year slashed in half.

You may also be interested in...



Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs

In her first address as CEO, Emma Walmsley has shocked the market with a long list of changes for GSK, including a total makeover of the group's pharma unit. As a result, more than 30 R&D programs will be getting the axe and a 2011 commercialization partnership with Johnson & Johnson is on its way to the gallows.

How Will Pfizer Leverage External Innovation After BioNTech Jackpot?

Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.

Editor’s Pick Q3 2021: New Science In The Spotlight

The In Vivo team recently put a spotlight on innovation that might disrupt the pharma and medtech markets. Thinking about novel developments today that will impact the life sciences sector in the near future, we explored interesting new science, the convergence of R&D and technology, as well as what the future of surgery might look like.

Topics

Related Companies

UsernamePublicRestriction

Register

SC088762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel